Effect of Urocortins in Patients With Heart Failure

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Heart FailureEndothelium
Interventions
DRUG

Urocortin 2, Urocortin 3 and Substance P

"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."

Trial Locations (1)

EH16 4SA

Wellcome Trust Clinical Research Facility, Royal Infirmary of Edinburgh, Edinburgh

All Listed Sponsors
collaborator

NHS Lothian

OTHER_GOV

lead

University of Edinburgh

OTHER

NCT01599728 - Effect of Urocortins in Patients With Heart Failure | Biotech Hunter | Biotech Hunter